Was this page useful?

*Required Field

Research / News & Events/ News





« Back to listings

Idiopathic Pulmonary Fibrosis, commonly known as IPF, is a disease that causes excessive lung scarring -- leading to heavy coughing, difficult breathing and eventually, death.

While IPF currently has no known cure, research conducted by Dr. Martin Kolb and his colleagues around the world has resulted in the development of a treatment that could become accessible to Canadians in the near future.

After years of research, Dr. Kolb and his colleagues have discovered a new drug that slows down the progression of IPF by up to 50 percent in 2014.  The drug has recently been approved by Health Canada and is currently undergoing evaluation for coverage by OHIP.

Learn more about this story in the Summer Edition of our Innovator newsletter, and from our media partners below:

New treatment offers hope for an incurable disease - The Hamilton Spectator

Hamilton-led research offers new hope for a rare disease - AM900 CHML

Comments are closed.